{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:43:36Z","timestamp":1787615016403,"version":"build-2736575974"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>\n                    Tuberous sclerosis complex is an autosomal dominant genetic disease characterized by growth of benign tumors (hamartomas) in multiple organs, especially the kidneys, brain, heart, lungs, and skin. Tuberous sclerosis complex is usually caused by a mutation in either the\n                    <jats:italic toggle=\"yes\">tuberous sclerosis complex 1<\/jats:italic>\n                    or\n                    <jats:italic toggle=\"yes\">tuberous sclerosis complex 2<\/jats:italic>\n                    gene, resulting in constitutive activation of mammalian target of rapamycin signaling. Currently, mammalian target of rapamycin inhibitors are recommended in adult patients with tuberous sclerosis complex for the treatment of asymptomatic, growing renal angiomyolipoma that are &gt;3 cm in diameter and pediatric or adult patients with brain lesions (subependymal giant cell astrocytoma) that either are growing or are not amenable to surgical resection. Clinical evidence suggests that systemic administration of a mammalian target of rapamycin inhibitor may provide concurrent improvements in multiple lesions and symptoms of tuberous sclerosis complex. With the major paradigm shift in consensus guidelines toward screening at diagnosis and ongoing monitoring and with the recent availability of an effective oral treatment, it is important that nephrologists have a thorough understanding of our role in the management of patients with tuberous sclerosis complex. Because the various manifestations of tuberous sclerosis complex typically emerge at different periods during patients\u2019 lifetimes, patients will need to be followed throughout their lives. Unlike brain and cardiac lesions, renal lesions are more likely to emerge as patients age and can grow at any time. Considerations regarding long-term medication administration for the potential control of multiple tuberous sclerosis complex manifestations will need to be addressed; these include the most appropriate starting dose, appropriate doses for tumor shrinkage versus prevention of regrowth, and management of adverse events. Best practices and potential obstacles for nephrologists treating patients with tuberous sclerosis complex who have multiple manifestations are considered.\n                  <\/jats:p>","DOI":"10.2215\/cjn.08150816","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T20:40:23Z","timestamp":1489696823000},"page":"1196-1202","source":"Crossref","is-referenced-by-count":26,"title":["Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex"],"prefix":"10.2215","volume":"12","author":[{"given":"Joshua A.","family":"Samuels","sequence":"first","affiliation":[{"name":"Renal Disease and Hypertension, Pediatric Nephrology and Hypertension, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-0030-1269906","article-title":"Tuberous sclerosis complex: Neurological, renal and pulmonary manifestations","volume":"41","author":"Franz","year":"2010","journal-title":"Neuropediatrics"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N Engl J Med"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/B978-0-444-52891-9.00038-5","article-title":"Tuberous sclerosis","volume":"111","author":"Curatolo","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1053\/j.ajkd.2011.10.013","article-title":"Tuberous sclerosis complex-associated angiomyolipomas: Focus on mTOR inhibition","volume":"59","author":"Budde","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/adc.2005.081703","article-title":"Congenital subependymal giant cell astrocytoma diagnosed on fetal MRI","volume":"91","author":"Hussain","year":"2006","journal-title":"Arch Dis Child"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1464-410X.2004.05046.x","article-title":"An epidemiological study of renal pathology in tuberous sclerosis complex","volume":"94","author":"O\u2019Callaghan","year":"2004","journal-title":"BJU Int"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.ki.5001853","article-title":"Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors","volume":"70","author":"Rakowski","year":"2006","journal-title":"Kidney Int"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1523-1755.2004.00838.x","article-title":"Renal angiomyolipomata","volume":"66","author":"Bissler","year":"2004","journal-title":"Kidney Int"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1159\/000320891","article-title":"Tuberous sclerosis complex renal disease","volume":"118","author":"Dixon","year":"2011","journal-title":"Nephron, Exp Nephrol"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s00467-004-1795-3","article-title":"Tuberous sclerosis and the kidney: From mesenchyme to epithelium, and beyond","volume":"20","author":"Henske","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1086\/514888","article-title":"Renal cystic disease in tuberous sclerosis: Role of the polycystic kidney disease 1 gene","volume":"61","author":"Sampson","year":"1997","journal-title":"Am J Hum Genet"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s11940-013-0249-2","article-title":"Management of CNS-related disease manifestations in patients with tuberous sclerosis complex","volume":"15","author":"Krueger","year":"2013","journal-title":"Curr Treat Options Neurol"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pediatrneurol.2013.12.004","article-title":"Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients","volume":"50","author":"Kotulska","year":"2014","journal-title":"Pediatr Neurol"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00381-002-0700-2","article-title":"Subependymal giant cell astrocytoma in children with tuberous sclerosis","volume":"19","author":"Cuccia","year":"2003","journal-title":"Childs Nerv Syst"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s11940-011-0123-z","article-title":"Subependymal giant cell astrocytoma (SEGA) treatment update","volume":"13","author":"Campen","year":"2011","journal-title":"Curr Treat Options Neurol"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.pediatrneurol.2013.08.017","article-title":"Subependymal giant cell astrocytoma: Diagnosis, screening, and treatment. Recommendations from the international tuberous sclerosis complex consensus conference 2012","volume":"49","author":"Roth","year":"2013","journal-title":"Pediatr Neurol"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/0883073813501870","article-title":"Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: Considerations for surgical or pharmacotherapeutic intervention","volume":"29","author":"Wheless","year":"2014","journal-title":"J Child Neurol"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2009.02567.x","article-title":"Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature","volume":"16","author":"Adriaensen","year":"2009","journal-title":"Eur J Neurol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1528-1167.2007.01035.x","article-title":"Tuberous sclerosis complex and epilepsy: Recent developments and future challenges","volume":"48","author":"Holmes","year":"2007","journal-title":"Epilepsia"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1586\/ern.13.49","article-title":"mTOR inhibitors as a new therapeutic option for epilepsy","volume":"13","author":"Curatolo","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejpn.2013.06.002","article-title":"Everolimus in tuberous sclerosis patients with intractable epilepsy: A treatment option?","volume":"17","author":"Wiegand","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awiak","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/08880018.2012.734896","article-title":"Cardiac rhabdomyomas associated with tuberous sclerosis complex in 11 children: Presentation to outcome","volume":"30","author":"Kocaba\u015f","year":"2013","journal-title":"Pediatr Hematol Oncol"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"591","DOI":"10.4065\/75.6.591","article-title":"High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex","volume":"75","author":"Costello","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5694\/mja12.11567","article-title":"Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis","volume":"199","author":"Mohammadieh","year":"2013","journal-title":"Med J Aust"},{"key":"B27-20230813","first-page":"211","article-title":"Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex","volume":"7","author":"Franz","year":"2013","journal-title":"Biologics"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.ejhg.5201402","article-title":"Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: Genotype--phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex","volume":"13","author":"Sancak","year":"2005","journal-title":"Eur J Hum Genet"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","article-title":"Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34","volume":"277","author":"van Slegtenhorst","year":"1997","journal-title":"Science"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","article-title":"Identification and characterization of the tuberous sclerosis gene on chromosome 16","volume":"75","year":"1993","journal-title":"Cell"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/17460441.2011.558079","article-title":"Research and innovation in the development of everolimus for oncology","volume":"6","author":"Lebwohl","year":"2011","journal-title":"Expert Opin Drug Discov"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1-TSC2 complex: A molecular switchboard controlling cell growth","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem J"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1749-6632.2009.05117.x","article-title":"The tuberous sclerosis complex","volume":"1184","author":"Orlova","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase structure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2217\/fon.12.146","article-title":"Everolimus (RAD001): First systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"8","author":"J\u00f3zwiak","year":"2012","journal-title":"Future Oncol"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: Recommendations of the 2012 international tuberous sclerosis complex consensus conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.urology.2007.07.045","article-title":"The role of partial nephrectomy for the management of sporadic renal angiomyolipoma","volume":"70","author":"Boorjian","year":"2007","journal-title":"Urology"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","article-title":"Multicenter phase 2 trial of sirolimus for tuberous sclerosis: Kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease","volume":"6","author":"Dabora","year":"2011","journal-title":"PLoS One"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: A phase 2 trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1824-7288-39-57","article-title":"Is mTOR inhibition a systemic treatment for tuberous sclerosis?","volume":"39","author":"Moavero","year":"2013","journal-title":"Ital J Pediatr"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"B46-20230813","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1542\/peds.2012-3607","article-title":"Possible prevention of tuberous sclerosis complex lesions","volume":"132","author":"Kotulska","year":"2013","journal-title":"Pediatrics"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"e1335","DOI":"10.1542\/peds.2010-2910","article-title":"Regression of a cardiac rhabdomyoma in a patient receiving everolimus","volume":"127","author":"Tiberio","year":"2011","journal-title":"Pediatrics"},{"key":"B48-20230813","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1097\/MPH.0000000000000005","article-title":"Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus","volume":"36","author":"Aguilera","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"B49-20230813","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00381-013-2170-0","article-title":"Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex","volume":"29","author":"Cappellano","year":"2013","journal-title":"Childs Nerv Syst"},{"key":"B50-20230813","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4329\/wjr.v8.i3.308","article-title":"Angiographic and volumetric effects of mammalian target of rapamycin inhibitors on angiomyolipomas in tuberous sclerosis","volume":"8","author":"Sheth","year":"2016","journal-title":"World J Radiol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201707000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:36:37Z","timestamp":1786368997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201707000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.08150816","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]}}}